CSL Behring Signs Agreements With Canadian Blood Services and Hema-Quebec to Supply Life-Saving... (in theory the agent responsible for theC...)

CSL Behring Signs Agreements With Canadian Blood Services and Hema-Quebec to Supply Life-Saving Therapies

Date:4/3/2008

in theory, the agent responsible for the Creutzfeldt-Jacob disease.

In some cases, patients may develop inhibitors of Factor VIII. These correspond to a patient's own antibodies which are directed against the Factor VIII present in Helixate(R) FS or Humate-P(R).

For more information about Helixate(R) FS and Humate-P, please contact: CSL Behring Canada, 1-866-773-7721.

About Immune Deficiency Disorders

Primary Immune Deficiencies (PIDs) are a group of disorders, usually genetic in nature, that cause a malfunction of the immune system, either in part or in totality, thus preventing the patient from fighting off infections caused by everyday microorganisms. For individuals with PID - many of them children - infections may not improve, as it would generally be expected, following an antibiotic treatment; this can in turn lead to recurrent infections. As a result, patients may face repeated rounds of antibiotics or, in some severe cases of PID, be hospitalized repeatedly for treatment. Repeated infections can lead to organ damage, which, over time, can become life-threatening. Some infections, such as meningitis, may even result in death.

Nearly 100 types of PIDs exist. Most are inherited, but in some cases the cause is unknown. No single treatment works for all of the different types. Infusions of replacement antibodies (immunoglobulins or Ig) can help supplement the immune system to prevent infection in nearly three-quarters of those people living with PID whose disease is tied to an antibody deficiency.

About Privigen(R) and Vivaglobin(R) Privigen(R) and Vivaglobin(R) are human plasma-derived therapeutic products containing a broad spectrum of immunoglobulins administered as replacement therapy in order to increase the antibody levels in patients with immune deficiencies.

Privigen(R) is an immunoglobulin (Ig) preparation designed to be administered via intravenous infusion. What sets it apart from other intravenous Ig
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7 8
Related biology technology :

1. CSL Behring Expands Into Middle East Market with Haemate(R) P
2. Siemens Completes Acquisition of Dade Behring
3. Siemens Receives EU Antitrust Clearance for Acquisition of Dade Behring
4. AMDL Signs Exclusive Licensing Agreement for Human Papilloma Virus Diagnostic Test Kit in Certain Asian Countries
5. Pharsight Signs Two New DMX(R) License Customers
6. Siemens Signs Multi-Year Agreement With Cleveland Clinic to Deploy Enterprise-Wide Cardiology PACS
7. WaferGen Signs Exclusive Distribution Agreement for SmartSlide(TM) Micro-Incubation System in Germany
8. Cardiac Science Signs Letter of Intent With Misys Healthcare Systems to Connect With Their EMR Systems
9. WaferGen Signs Exclusive Distribution Agreement for SmartSlide(TM) Micro-Incubation System in United Kingdom and France
10. Millennium Biotechnologies, Inc. Signs Marketing and Distribution Agreement with Ferring Pharmaceuticals
11. PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia

Post Your Comments:

CSL Behring Signs Agreements With Canadian Blood Services and Hema-Quebec to Supply Life-Saving...(in theory the agent responsible for theC...)